237 related articles for article (PubMed ID: 37823195)
1. Ouabain enhances renal cyst growth in a slowly progressive mouse model of autosomal dominant polycystic kidney disease.
Trant J; Sanchez G; McDermott JP; Blanco G
Am J Physiol Renal Physiol; 2023 Dec; 325(6):F857-F869. PubMed ID: 37823195
[TBL] [Abstract][Full Text] [Related]
2. Metformin improves relevant disease parameters in an autosomal dominant polycystic kidney disease mouse model.
Pastor-Soler NM; Li H; Pham J; Rivera D; Ho PY; Mancino V; Saitta B; Hallows KR
Am J Physiol Renal Physiol; 2022 Jan; 322(1):F27-F41. PubMed ID: 34806449
[TBL] [Abstract][Full Text] [Related]
3. Ouabain Regulates CFTR-Mediated Anion Secretion and Na,K-ATPase Transport in ADPKD Cells.
Jansson K; Venugopal J; Sánchez G; Magenheimer BS; Reif GA; Wallace DP; Calvet JP; Blanco G
J Membr Biol; 2015 Dec; 248(6):1145-57. PubMed ID: 26289599
[TBL] [Abstract][Full Text] [Related]
4. Endogenous concentrations of ouabain act as a cofactor to stimulate fluid secretion and cyst growth of in vitro ADPKD models via cAMP and EGFR-Src-MEK pathways.
Jansson K; Nguyen AN; Magenheimer BS; Reif GA; Aramadhaka LR; Bello-Reuss E; Wallace DP; Calvet JP; Blanco G
Am J Physiol Renal Physiol; 2012 Oct; 303(7):F982-90. PubMed ID: 22859406
[TBL] [Abstract][Full Text] [Related]
5. The chloride channel CFTR is not required for cyst growth in an ADPKD mouse model.
Talbi K; Cabrita I; Kraus A; Hofmann S; Skoczynski K; Kunzelmann K; Buchholz B; Schreiber R
FASEB J; 2021 Oct; 35(10):e21897. PubMed ID: 34473378
[TBL] [Abstract][Full Text] [Related]
6. Inhibiting the HSP90 chaperone slows cyst growth in a mouse model of autosomal dominant polycystic kidney disease.
Seeger-Nukpezah T; Proia DA; Egleston BL; Nikonova AS; Kent T; Cai KQ; Hensley HH; Ying W; Chimmanamada D; Serebriiskii IG; Golemis EA
Proc Natl Acad Sci U S A; 2013 Jul; 110(31):12786-91. PubMed ID: 23858461
[TBL] [Abstract][Full Text] [Related]
7. Ouabain binds with high affinity to the Na,K-ATPase in human polycystic kidney cells and induces extracellular signal-regulated kinase activation and cell proliferation.
Nguyen AN; Wallace DP; Blanco G
J Am Soc Nephrol; 2007 Jan; 18(1):46-57. PubMed ID: 17151336
[TBL] [Abstract][Full Text] [Related]
8. The tyrosine-kinase inhibitor Nintedanib ameliorates autosomal-dominant polycystic kidney disease.
Jamadar A; Suma SM; Mathew S; Fields TA; Wallace DP; Calvet JP; Rao R
Cell Death Dis; 2021 Oct; 12(10):947. PubMed ID: 34650051
[TBL] [Abstract][Full Text] [Related]
9. Metformin induces lactate accumulation and accelerates renal cyst progression in Pkd1-deficient mice.
Chang MY; Tsai CY; Chou LF; Hsu SH; Yang HY; Hung CC; Tian YC; Ong ACM; Yang CW
Hum Mol Genet; 2022 May; 31(10):1560-1573. PubMed ID: 34957500
[TBL] [Abstract][Full Text] [Related]
10. Cyclin-Dependent Kinase 1 Activity Is a Driver of Cyst Growth in Polycystic Kidney Disease.
Zhang C; Balbo B; Ma M; Zhao J; Tian X; Kluger Y; Somlo S
J Am Soc Nephrol; 2021 Jan; 32(1):41-51. PubMed ID: 33046531
[TBL] [Abstract][Full Text] [Related]
11. STAT5 drives abnormal proliferation in autosomal dominant polycystic kidney disease.
Fragiadaki M; Lannoy M; Themanns M; Maurer B; Leonhard WN; Peters DJ; Moriggl R; Ong AC
Kidney Int; 2017 Mar; 91(3):575-586. PubMed ID: 28104302
[TBL] [Abstract][Full Text] [Related]
12. Triptolide reduces cyst formation in a neonatal to adult transition Pkd1 model of ADPKD.
Leuenroth SJ; Bencivenga N; Chahboune H; Hyder F; Crews CM
Nephrol Dial Transplant; 2010 Jul; 25(7):2187-94. PubMed ID: 20139063
[TBL] [Abstract][Full Text] [Related]
13. Metabolic reprogramming in a slowly developing orthologous model of polycystic kidney disease.
Hopp K; Kleczko EK; Gitomer BY; Chonchol M; Klawitter J; Christians U; Klawitter J
Am J Physiol Renal Physiol; 2022 Mar; 322(3):F258-F267. PubMed ID: 35037466
[TBL] [Abstract][Full Text] [Related]
14. Pkd2 Deficiency in Embryonic Aqp2 + Progenitor Cells Is Sufficient to Cause Severe Polycystic Kidney Disease.
Tsilosani A; Gao C; Chen E; Lightle AR; Shehzad S; Sharma M; Tran PV; Bates CM; Wallace DP; Zhang W
J Am Soc Nephrol; 2024 Apr; 35(4):398-409. PubMed ID: 38254271
[TBL] [Abstract][Full Text] [Related]
15. A study of sirolimus and mTOR kinase inhibitor in a hypomorphic
Holditch SJ; Brown CN; Atwood DJ; Lombardi AM; Nguyen KN; Toll HW; Hopp K; Edelstein CL
Am J Physiol Renal Physiol; 2019 Jul; 317(1):F187-F196. PubMed ID: 31042058
[TBL] [Abstract][Full Text] [Related]
16. The lonidamine derivative H2-gamendazole reduces cyst formation in polycystic kidney disease.
Sundar SV; Zhou JX; Magenheimer BS; Reif GA; Wallace DP; Georg GI; Jakkaraj SR; Tash JS; Yu ASL; Li X; Calvet JP
Am J Physiol Renal Physiol; 2022 Oct; 323(4):F492-F506. PubMed ID: 35979967
[TBL] [Abstract][Full Text] [Related]
17. Cyst growth in ADPKD is prevented by pharmacological and genetic inhibition of TMEM16A in vivo.
Cabrita I; Kraus A; Scholz JK; Skoczynski K; Schreiber R; Kunzelmann K; Buchholz B
Nat Commun; 2020 Aug; 11(1):4320. PubMed ID: 32859916
[TBL] [Abstract][Full Text] [Related]
18. Cux1 promotes cell proliferation and polycystic kidney disease progression in an ADPKD mouse model.
Porath B; Livingston S; Andres EL; Petrie AM; Wright JC; Woo AE; Carlton CG; Baybutt R; Vanden Heuvel GB
Am J Physiol Renal Physiol; 2017 Oct; 313(4):F1050-F1059. PubMed ID: 28701314
[TBL] [Abstract][Full Text] [Related]
19. Mitochondrial Abnormality Facilitates Cyst Formation in Autosomal Dominant Polycystic Kidney Disease.
Ishimoto Y; Inagi R; Yoshihara D; Kugita M; Nagao S; Shimizu A; Takeda N; Wake M; Honda K; Zhou J; Nangaku M
Mol Cell Biol; 2017 Dec; 37(24):. PubMed ID: 28993480
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of TGF-β1 induces renal fibrosis and accelerates the decline in kidney function in polycystic kidney disease.
Zhang Y; Dai Y; Raman A; Daniel E; Metcalf J; Reif G; Pierucci-Alves F; Wallace DP
Am J Physiol Renal Physiol; 2020 Dec; 319(6):F1135-F1148. PubMed ID: 33166182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
